Physician profile
Karin E Baughman
NPI 1811340268
$15,876.19
in general payments reported to CMS, 2019-2025
11 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $1,006 · 2023: $7,030 · 2024: $4,979 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $1,701 · Travel and Lodging: $385 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,336.00 |
| Food and Beverage | $1,700.56 |
| Travel and Lodging | $385.01 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13,421.22 | 2022-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $537.34 | 2021-2023 | Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $406.42 | 2023-2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $383.24 | 2021-2022 | |
| Abbvie INC. | $347.17 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $209.77 | 2022-2023 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $146.15 | 2024 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.04 | 2023 | |
| Genzyme Corporation | $109.86 | 2023 | |
| Eisai INC. | $100.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $94.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Baughman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.